Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00330252
Status:
COMPLETED
Last Update Posted:
2016-05-13
First Post:
2006-05-25
Brief Title:
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-05
Start Date Type:
None
Primary Completion Date:
2013-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-01
Completion Date Type:
ACTUAL
First Submit Date:
2006-05-25
First Submit QC Date:
May 25 2006
Study First Post Date:
2006-05-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-05-11
Last Update Post Date:
2016-05-13
Last Update Post Date Type:
ESTIMATED